Real-life data for tenofovir alafenamide fumarate treatment of hepatitis B: The pythagoras cohort

Basit Öğe Kaydı
dc.authorid0000-0002-0760-5681en_US
dc.contributor.authorKaraşahin, Ömer
dc.contributor.authorKalkan, İrem Akdemir
dc.contributor.authorDal, Tuba
dc.contributor.authorToplu, Sibel Altunışık
dc.contributor.authorHarputoğlu, Murat
dc.contributor.authorMete, Ayşe Özlem
dc.contributor.authorKömür, Süheyla
dc.contributor.authorSarigül, Figen
dc.contributor.authorYıldız, Yeşim
dc.contributor.authorEsmer, Fatih
dc.contributor.authorKandemir, Özlem
dc.contributor.authorNazik, Selçuk
dc.contributor.authorİnan, Dilara
dc.contributor.authorAkgül, Fethiye
dc.contributor.authorKaya, Şafak
dc.contributor.authorTunç, Nurettin
dc.contributor.authorBalin, Şafak Özer
dc.contributor.authorBayındır, Yaşar
dc.contributor.authorTaşova, Yeşim
dc.contributor.authorAktar, Fesih
dc.contributor.authorÖren, Meryem Merve
dc.contributor.authorAyhan, Merve
dc.contributor.authorDemir, Yakup
dc.contributor.authorÇelen, Mustafa Kemal
dc.date.accessioned2022-07-01T06:08:50Z
dc.date.available2022-07-01T06:08:50Z
dc.date.issued2021en_US
dc.departmentDicle Üniversitesi, Tıp Fakültesi, Dahili Tıp Bilimleri Bölümü, Çocuk Sağlığı ve Hastalıkları Ana Bilim Dalıen_US
dc.descriptionWOS:000635211600001
dc.description.abstractBackground: Chronic hepatitis B (CHB) is a viral infection that can result in life-threatening conditions, such as hepatocellular carcinoma and cirrhosis. Tenofovir, which is used for the treatment of CHB, is a nucleotide analog that inhibits HBV-DNApolymerase and has two formulations: disoproxil and alafenamide. In contrast to tenofovir disoproxil fumarate (TDF), tenofovir alafenamide fumarate (TAF) penetrates the whole hepatocyte without being eliminated due to its longer plasma half-life and greater plasma stability. As a result, side effects such as proximal renal tubulopathy and loss of bone density are less common in the treatment of TAF and have similar efficacy to TDF. Objectives: The purpose of the study was to evaluate the effectiveness and reliability of TAF using real-life data. Methods: This retrospective cohort study was carried out in secondary or tertiary healthcare centers in southern Turkey. A total of 480 patients aged 18 years and older were administered TAF for an appropriate indication by the infectious diseases and gastroenterology clinics of the healthcare centers participating in this study. The data collected at t = 0, t =3, and t = 6 months of treatment were analyzed. The chi-square, Mann-Whitney U, Friedman, Wilcoxon, Cochran's Q, and McNemar's tests were used. Results: The mean age of the patients was 47.40 +/- 14.5, and 327 of them (68.1%) were male. A total of 78.1% of the 480 patients who underwent the TAF treatment had previous antiviral therapy experience (TDF, n =340; 70.8 %), and 21.9% were treatment-naive. The most common reasons for the initiation of TAF treatment were the use of drugs affecting bone mineral density (BMD) (42.9%) and osteoporosis (22.3%). Patients who had taken TDF experienced a significant improvement in glomerular filtration rate (GFR), hip and spine T-scores, and phosphorus levels from t = 0 months tot = 6 months after switching to TAF (P < 0.05). For this group, no statistically significant difference was observed concerning LDL and cholesterol levels from t= 0 months to t = 6 months. Side effects were reported by 5.7% of patients in the third month and 7.1% in the sixth month, with the most common side effect being hair loss (1%). Conclusions: TAF was found to be an effective and safe alternative to TDF with lower incidences of its long-term effects, such as nephrotoxicity and decreased bone density.en_US
dc.identifier.citationKaraşahin, Ö., Kalkan, İ.A., Dal, T., Toplu, S.A., Harputoğlu, M., Mete, A.Ö. ve diğerleri. (2021). Real-life data for tenofovir alafenamide fumarate treatment of hepatitis B: The pythagoras cohort. Hepatitis Monthly, 21(2), 1-9. http://doi.org/10.5812/hepatmon.104943en_US
dc.identifier.doi10.5812/hepatmon.104943
dc.identifier.endpage9en_US
dc.identifier.issn1735-143X
dc.identifier.issn1735-3408
dc.identifier.issue2en_US
dc.identifier.scopus2-s2.0-85105532673
dc.identifier.scopusqualityQ3
dc.identifier.startpage1en_US
dc.identifier.urihttps://brieflands.com/articles/hepatmon-104943.html
dc.identifier.urihttps://hdl.handle.net/11468/10083
dc.identifier.volume21en_US
dc.identifier.wosWOS:000635211600001
dc.identifier.wosqualityQ4
dc.indekslendigikaynakWeb of Science
dc.indekslendigikaynakScopus
dc.institutionauthorAktar, Fesih
dc.institutionauthorÇelen, Mustafa Kemal
dc.language.isoenen_US
dc.publisherKowsar Publicationen_US
dc.relation.ispartofHepatitis Monthly
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectBone mineral densityen_US
dc.subjectHepatitis Ben_US
dc.subjectChronic Hepatitis Ben_US
dc.subjectGlomerular filtration rateen_US
dc.subjectTenofovir Alafenamideen_US
dc.subjectReal lifeen_US
dc.subjectTenofovir Disoproxilen_US
dc.titleReal-life data for tenofovir alafenamide fumarate treatment of hepatitis B: The pythagoras cohorten_US
dc.titleReal-life data for tenofovir alafenamide fumarate treatment of hepatitis B: The pythagoras cohort
dc.typeArticleen_US

Dosyalar

Orijinal paket
Listeleniyor 1 - 1 / 1
[ X ]
İsim:
Real-life Data for Tenofovir Alafenamide Fumarate Treatment of Hepatitis B the Pythagoras Cohort.pdf
Boyut:
165.51 KB
Biçim:
Adobe Portable Document Format
Açıklama:
Makale Dosyası
İndir
Lisans paketi
Listeleniyor 1 - 1 / 1
[ X ]
İsim:
license.txt
Boyut:
1.44 KB
Biçim:
Item-specific license agreed upon to submission
Açıklama:
İndir

Koleksiyon

Dahili Tıp Bilimleri Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu
WoS İndeksli Yayınlar Koleksiyonu

We collect and process your personal information for the following purposes: Authentication, Preferences, Acknowledgement and Statistics.
To learn more, please read our privacy policy.

Customize